Stock Events

Stock Events

GT Biopharma 

$0.2410
35
-$0.01-4.52% Friday 20:00
-$0.00-0.46%Friday 23:47After hours

Statistics

Day High
0.2412
Day Low
0.2405
52W High
1.37
52W Low
0.2221
Volume
1,374
Avg. Volume
-
Mkt Cap
10.87M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.67
-1.14
-0.61
-0.08
Expected EPS
-0.1
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-34.45MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GTBP. It's not an investment recommendation.
Altria Group
5
MO
Netflix
5
NFLX
Apple
4
AAPL
Realty Income
4
O

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a biopharmaceutical company that competes in the development of innovative therapies, including oncology, similar to GT Biopharma's focus on targeted immuno-oncology treatments.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biotech firm with a strong emphasis on cancer and serious illness treatments, directly competing with GT Biopharma's cancer therapy portfolio.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb is involved in discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases, including cancer, making it a direct competitor.
Merck
MRK
Mkt Cap366B
Merck operates in the pharmaceutical sector with a significant focus on cancer treatments and immunotherapy, competing with GT Biopharma's cancer-focused therapies.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global biopharmaceutical company with a broad range of drug development including oncology, competing in the same space as GT Biopharma.
Novartis
NVS
Mkt Cap292.35B
Novartis focuses on a wide range of healthcare areas including innovative medicines in oncology, directly competing with GT Biopharma's innovative cancer treatments.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a leader in research-focused healthcare with strengths in pharmaceuticals and diagnostics, including cancer, making it a competitor.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca operates in the biopharmaceutical sector focusing on the development of new medicines in oncology, among other areas, competing with GT Biopharma.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical segment, develops treatments for various diseases, including cancer, competing in the same therapeutic area as GT Biopharma.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is known for its innovation in biotechnology, including developing treatments for cancer, making it a competitor in the biopharmaceutical field.

About

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
Show more...
CEO
Michael Martin Breen
Employees
1
Country
United States
ISIN
US36254L3087
WKN
000A402U5

Listings

MU
DE
OXI.MU
STU
DE
OXI1.STU
MU
DE
OXIA.MU
F
DE
OXIA.F

0 Comments

Share your thoughts

FAQ

What is GT Biopharma stock price today?▼
The current price of GTBP is $0.24 USD — it has decreased by -4.52% in the past 24 hours. Watch GT Biopharma stock price performance more closely on the chart.
What is GT Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange GT Biopharma stocks are traded under the ticker GTBP.
Is GT Biopharma stock price growing?▼
GTBP stock has fallen by -19.67% compared to the previous week, the month change is a -24.09% fall, over the last year GT Biopharma has showed a -74.5% decrease.
What is GT Biopharma market cap?▼
Today GT Biopharma has the market capitalization of 10.87M
When is the next GT Biopharma earnings date?▼
GT Biopharma is going to release the next earnings report on November 11, 2026.
What were GT Biopharma earnings last quarter?▼
GTBP earnings for the last quarter are -0.12 USD per share, whereas the estimation was -0.08 USD resulting in a -50% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is GT Biopharma revenue for the last year?▼
GT Biopharma revenue for the last year amounts to 0 USD.
What is GT Biopharma net income for the last year?▼
GTBP net income for the last year is -34.45M USD.
How many employees does GT Biopharma have?▼
As of September 05, 2026, the company has 1 employees.
In which sector is GT Biopharma located?▼
GT Biopharma operates in the Health & Wellness sector.
When did GT Biopharma complete a stock split?▼
The last stock split for GT Biopharma was on February 05, 2024 with a ratio of 1:30.
Where is GT Biopharma headquartered?▼
GT Biopharma is headquartered in SAN FRANCISCO, United States.